Alfonso Fernando, Pérez-Vizcayno María J, Cruz Angel, García Javier, Jimenez-Quevedo Pilar, Escaned Javier, Hernandez Rosana
Interventional Cardiology, Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
EuroIntervention. 2009 May;5 Suppl D:D70-8.
Treatment of patients with in-stent restenosis (ISR) remains a technical challenge. This problem has been reduced since the advent of drug-eluting stents (DES), but continues to represent a significant burden during daily practice in interventional cardiology. Treatment of ISR after bare-metal stent implantation has evolved and currently DES constitute the intervention of choice. However, DES may also develop ISR. The best therapeutic alternative for patients suffering from ISR after DES implantation remains to be elucidated. This review will focus on treatment of patients with ISR emphasising currently available alternatives, technical issues, limitations and future perspectives.
支架内再狭窄（ISR）患者的治疗仍然是一项技术挑战。自药物洗脱支架（DES）问世以来，这个问题有所减少，但在介入心脏病学的日常实践中仍然是一个重大负担。裸金属支架植入术后ISR的治疗已经有所发展，目前DES是首选的干预措施。然而，DES也可能发生ISR。DES植入术后发生ISR的患者的最佳治疗选择仍有待阐明。本综述将重点关注ISR患者的治疗，强调目前可用的替代方案、技术问题、局限性和未来前景。
